Robert Jones speaks to Francesca Lake, Managing Commissioning Editor.
Robert completed his PhD in molecular biology at the Beatson Institute for Cancer Research (Glasgow, UK) and is currently the senior lecturer in medical oncology at the University of Glasgow (UK) and a consultant at the Beatson West of Scotland Cancer Centre (Glasgow, UK). He is involved in the management of prostate, bladder and kidney cancers in the clinic and performs collaborative translational research with researchers from the Beatson Institute. He also manages Phase I, II and III trials in the urological cancer field, and is Chief Investigator of the TOUCAN and PLUTO trials (urothelial cancer), SAPROCAN and MAdCaP trials (prostate cancer), and the UK component of the ASPEN trial (renal cell carcinoma). Recently, he has been involved in the COMPARZ trial, which compared pazopanib with sunitinib in renal cell carcinoma patients. He is director of the Glasgow Cancer Research UK Clinical Trials Unit and is an active member of the UK National Cancer Research Institute Clinical Studies Groups in urology.
Written by:
Jones R. Are you the author?
Beatson West of Scotland Cancer Centre, Level 3, 1053 Great Western Road, Glasgow, G12 0YN, UK.
Reference: Future Oncol. 2013 Feb;9(2):149-52.
doi: 10.2217/fon.12.176
PubMed Abstract
PMID: 23414465
UroToday.com Prostate Cancer Section
